Definium Therapeutics, Inc. filed a current report on Form 8-K on September 8, 2026, disclosing that the U.S. Food and Drug Administration granted breakthrough designation to its DT120 ODT program for the treatment of major depressive disorder.
Key Highlights
- Breakthrough Designation: The FDA granted breakthrough designation to Definium Therapeutics' DT120 ODT program.
- Indication: The designation covers treatment of major depressive disorder.
- Announcement Date: The company issued a press release on September 8, 2026, reporting the FDA action.
- Exchange Listing: Common Shares trade on NASDAQ:DFTX.
- Emerging Growth Company: The registrant is classified as an emerging growth company under applicable securities law.
FDA Breakthrough Designation Granted to Definium Therapeutics for DT120 ODT in Major Depressive Disorder
According to the filing, Definium Therapeutics, Inc. disclosed on September 8, 2026, that the U.S. Food and Drug Administration has granted breakthrough designation to the company's DT120 ODT program for the treatment of major depressive disorder. The disclosure was made under Item 8.01 (Other Events) of the Form 8-K filed with the Securities and Exchange Commission. The company is incorporated in British Columbia and maintains its principal executive offices at One World Trade Center, Suite 8500, New York, New York 10007.
The filing states that a press release dated September 8, 2026, containing the full announcement, is attached as Exhibit 99.1 and incorporated by reference into the current report. No additional financial statements were filed in connection with this disclosure. The report was signed by Robert Barrow, identified in the filing as Chief Executive Officer of Definium Therapeutics, Inc.
The registrant's Common Shares are listed on The Nasdaq Stock Market LLC under the trading symbol DFTX, as stated in the cover page securities registration table. The company has indicated that it is an emerging growth company as defined under Rule 405 of the Securities Act of 1933 and Rule 12b-2 of the Securities Exchange Act of 1934, and has not elected to use the extended transition period for complying with new or revised financial accounting standards.
What Was Disclosed
Definium Therapeutics reported via an 8-K filing dated September 8, 2026, that the FDA granted breakthrough designation to its DT120 ODT program for major depressive disorder. A press release was attached as Exhibit 99.1.




Please wait processing your request...